FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.



The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).1

The agent is currently under exploration in the first-in-human phase 1 GLEAN-1 trial (NCT04735471) in NHL, which announced positive interim data in December 2021.2

“Fast track designation represents an important milestone in the clinical development of ADI-001,” Chen Schor, president and chief executive officer of Adicet Bio, said in a news release. “We believe ADI-001 is unique in that it is designed to target malignant B cells by leveraging the innate and adaptive receptors found naturally on gamma delta T cells with the added benefit of an engineered anti CD20 CAR. We remain optimistic about the potential of our program and look forward to reporting additional data from the phase 1 trial of ADI-001 in the first half of 2022.”

ADI-001 is an investigational allogeneic gamma delta CAR T-cell therapy that targets malignant B cells via a CD20-directed CAR and the innate gamma delta and T-cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with a CD20-directed CAR have shown robust antitumor activity in preclinical models, leading to long-term disease stabilization.

The open-label, multi-center phase 1 study consists of 3 parts. Part 1 consists of a dose-escalation phase and will enroll approximately 30 patients with relapsed/refractory B-cell NHL. Three cell dose levels (3E7, 1E8, or 3E8) will be evaluated in part 1, using the 3 + 3 dose-escalation scheme. In part 2, approximately 36 patients will be enrolled into 3 disease-specific cohorts. Part 3 will evaluate the safety and efficacy of ADI-001 plus low-dose subcutaneous IL-2 and will enroll approximately 12 patients.3

To be eligible for enrollment, patients must have a diagnosed B-cell malignancy that has relapsed or is refractory to at least 2 prior treatment regimens, be at least 18 years of age, have an ECOG performance status of 0 or 1, and have measurable disease per Lugano 2014 and Response Evaluation Criteria in Lymphoma 2017.

The primary objective of part 1 is to determine the incidence of dose-limiting toxicity and the maximum tolerated dose (MTD) of ADI-001. In parts 2 and 3, the MTD of ADI-001 alone or in combination with IL-2 will be further evaluated for safety and antitumor activity. The secondary objectives for parts 1, 2 and 3 include the evaluation of ADI-001’s pharmacokinetics, immunogenicity, and antitumor activity alone and in combination with IL-2.

Prior results from the trial showed that as of the November 22, 2021 cutoff, 6 patients had been enrolled and received treatment with ADI-001. The first 2 patients enrolled in the lowest dose level did not reach the 28-day assessment and were not evaluable for efficacy per protocol.

Three of the four evaluable patients achieved responses, including 2 complete responses (CR) and 1 partial response (PR). Of these 4 patients, 3 received ADI-001 at the first dose level (30 million CAR+ cells) and 1 received ADI-001 at the second dose level (100 million CAR+ cells). In the first dose level, 1 patient achieved a CR, 1 patient achieved a PR, and 1 patient had progressive disease. In the second dose level, the first patient achieved a CR.

Of the 3 responders, 1 had diffuse large B-cell lymphoma and had received 5 prior lines of therapy, including 2 cycles of CD19-directed CAR T-cell therapy; 1 had follicular lymphoma transformed into a large B-cell tumor and had received 4 prior lines of therapy; and the third had mantle cell lymphoma and had received 5 prior lines of therapy.

Regarding safety, ADI-001 infusions were generally well-tolerated. No dose-limiting toxicities, graft-vs-host-disease, immune effector cell–associated neurotoxicity syndrome (ICANS) or grade 3 or higher cytokine release syndrome (CRS) had been reported by data cutoff.

Additionally, a significant increase in circulating IL-15 was reported during the first 28 days following lymphodepletion. Circulating ADI-001 was also found in the blood by quantitative polymerase chain reaction and by flow cytometry, demonstrating expansion of ADI-001. Increased levels of circulating IL-2 and IL-8 were also reported during the first 14 days after dosing, comparable with the time-to-peak for cytokines previously reported with autologous alpha-beta CAR T-cell therapy.

Notably, no meaningful increases in IL-6 were seen with ADI-001, except for 1 patient who experienced COVID-19 infection.


  1. Adicet Bio receives FDA fast track designation for lead candidate ADI-001. News release. Adicet Bio, Inc. April 19, 2022. Accessed April 20, 2022. https://bwnews.pr/3vwser0
  2. Adicet Bio announces positive interim clinical data from first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy. News release. December 6, 2021. Accessed April 20, 2022. https://bit.ly/38TCfGX
  3. Neelapu SS, Hamadani M, Stevens D, et al. A phase 1 safety and efficacy study of ADI-001 anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B cell malignancies, in monotherapy and combination with IL-2. Blood. 2021;138(suppl 1):2834. doi:10.1182/blood-2021-147581
Related Videos
Lakshimi Nayak, MD
Eunice Wang, MD
Expert on DLBCL
Tycel Phillips, MD
Expert on ALL
Michael Andreeff, MD, PhD
Brian C. Ball, MD
Mitchell E. Horwitz, MD
Bradley W. Christensen, MD
Jorge E. Cortes, MD
Related Content